

Table 19.30  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2006-2012

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	
Lymphoid Neoplasm	97,136	69.4 ( 69.0 , 69.8 )	89.7 ( 88.8 , 90.6 )	75.6 ( 75.2 , 76.1 )	59.0 ( 58.2 , 59.7 )			
1 Hodgkin Lymphoma	8,168	85.4 ( 84.4 , 86.3 )	96.7 ( 95.2 , 97.8 )	88.7 ( 87.7 , 89.6 )	54.3 ( 50.0 , 58.4 )			
2 Non-Hodgkin lymphoma	86,731	68.3 ( 67.9 , 68.8 )	88.0 ( 86.9 , 89.0 )	74.1 ( 73.6 , 74.6 )	59.6 ( 58.9 , 60.4 )			
2(a) Non-Hodgkin lymphoma, B-cell	79,652	68.8 ( 68.3 , 69.2 )	88.5 ( 87.2 , 89.7 )	75.1 ( 74.5 , 75.6 )	60.2 ( 59.4 , 61.0 )			
2(a) 1. Precursor Non-Hodgkin lymphoma, B-cell	4,284	68.6 ( 67.0 , 70.2 )	87.9 ( 86.4 , 89.3 )	38.5 ( 35.3 , 41.7 )	19.3 ( 14.0 , 25.2 )			
2(a) 2. Mature Non-Hodgkin lymphoma, B-cell	71,668	68.9 ( 68.4 , 69.4 )	90.5 ( 87.9 , 92.5 )	76.4 ( 75.9 , 77.0 )	60.6 ( 59.7 , 61.3 )			
2(a) 2.1. Chronic/Small/Prolymphocytic/ Mantle B-cell Non-Hodgkin lymphoma	18,803	77.4 ( 76.4 , 78.3 )	- ( - , - )	85.5 ( 84.4 , 86.5 )	70.9 ( 69.4 , 72.4 )			
2(a) 2.1.1. Chronic/Small lymphocytic leukemia/lymphoma	16,158	81.0 ( 79.9 , 82.0 )	- ( - , - )	88.7 ( 87.5 , 89.8 )	75.0 ( 73.3 , 76.5 )			
2(a) 2.1.2. Prolymphocytic leukemia, B-cell	67	48.5 ( 30.9 , 64.0 )	- ( - , - )	61.6 ( 34.5 , 80.3 )	40.5 ( 20.4 , 59.8 )			
2(a) 2.1.3. Mantle-cell lymphoma	2,578	55.5 ( 52.8 , 58.1 )	- ( - , - )	67.6 ( 64.2 , 70.9 )	43.9 ( 40.0 , 47.8 )			
2(a) 2.2. Lymphoplasmacytic lymphoma/ Waldenstrom macroglobulinemia	1,598	81.9 ( 78.2 , 84.9 )	- ( - , - )	88.4 ( 84.5 , 91.4 )	77.4 ( 72.0 , 81.9 )			
2(a) 2.2.1. Lymphoplasmacytic lymphoma	683	77.9 ( 72.2 , 82.6 )	- ( - , - )	84.0 ( 77.3 , 88.8 )	73.4 ( 65.0 , 80.1 )			
2(a) 2.2.2. Waldenstrom macroglobulinemia	915	84.9 ( 79.9 , 88.7 )	- ( - , - )	91.3 ( 85.6 , 94.8 )	80.6 ( 73.1 , 86.2 )			
2(a) 2.3. Diffuse large B-cell lymphoma (DLBCL)	18,472	62.0 ( 61.0 , 62.9 )	89.8 ( 85.1 , 93.0 )	69.0 ( 67.9 , 70.1 )	52.7 ( 51.1 , 54.3 )			
2(a) 2.3.1. DLBCL, NOS <sup>c</sup>	18,267	62.0 ( 61.1 , 62.9 )	90.3 ( 85.6 , 93.5 )	69.0 ( 67.9 , 70.1 )	52.8 ( 51.2 , 54.4 )			
2(a) 2.3.2. Intravascular large B-cell lymphoma	27	39.2 ( 16.8 , 61.1 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 2.3.3. Primary effusion lymphoma	50	23.4 ( 11.6 , 37.7 )	- ( - , - )	22.6 ( 10.4 , 37.7 )	- ( - , - )			
2(a) 2.3.4. Mediastinal large B-cell lymphoma	128	79.0 ( 68.1 , 86.5 )	- ( - , - )	84.4 ( 73.1 , 91.2 )	- ( - , - )			
2(a) 2.4. Burkitt lymphoma/leukemia	1,586	62.1 ( 59.4 , 64.7 )	89.4 ( 85.7 , 92.3 )	57.7 ( 54.3 , 60.9 )	36.2 ( 27.6 , 44.7 )			
2(a) 2.5. Marginal-zone lymphoma (MZL)	4,353	89.6 ( 87.7 , 91.2 )	100.0 ( - , - )	92.4 ( 90.5 , 93.9 )	86.5 ( 83.2 , 89.1 )			
2(a) 2.5.1. Splenic MZL	378	88.5 ( 81.2 , 93.0 )	- ( - , - )	83.4 ( 74.7 , 89.4 )	89.9 ( 80.5 , 94.9 )			
2(a) 2.5.2. Extranodal MZL, MALT <sup>c</sup> type	2,561	93.8 ( 91.3 , 95.6 )	100.0 ( - , - )	95.5 ( 93.3 , 97.0 )	91.5 ( 86.1 , 94.9 )			
2(a) 2.5.3. Nodal MZL	1,414	82.0 ( 78.4 , 85.0 )	- ( - , - )	88.0 ( 84.0 , 91.1 )	76.4 ( 70.3 , 81.3 )			
2(a) 2.6. Follicular lymphoma	8,896	86.5 ( 85.3 , 87.6 )	96.5 ( 75.8 , 99.6 )	90.2 ( 89.0 , 91.3 )	80.5 ( 78.0 , 82.7 )			
2(a) 2.7. Hairy-cell leukemia	1,224	93.1 ( 90.1 , 95.3 )	- ( - , - )	96.5 ( 93.8 , 98.0 )	83.7 ( 74.4 , 89.8 )			
2(a) 2.8. Plasma cell neoplasms	16,714	49.3 ( 48.2 , 50.3 )	- ( - , - )	60.8 ( 59.4 , 62.2 )	39.2 ( 37.7 , 40.7 )			
2(a) 2.8.1. Plasmacytoma	1,172	67.6 ( 63.7 , 71.2 )	- ( - , - )	76.5 ( 72.2 , 80.3 )	53.2 ( 45.8 , 60.1 )			
2(a) 2.8.2. Multiple myeloma/ plasma-cell leukemia	15,542	47.9 ( 46.8 , 49.0 )	- ( - , - )	59.2 ( 57.7 , 60.7 )	38.4 ( 36.9 , 40.0 )			
2(a) 2.9. Heavy chain disease	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(a) 3. Non-Hodgkin lymphoma, B-cell, NOS <sup>c</sup>	3,700	66.6 ( 64.3 , 68.9 )	91.9 ( 79.4 , 96.9 )	73.3 ( 70.4 , 76.0 )	60.9 ( 57.3 , 64.3 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). *Blood*. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

- Statistic not displayed due to less than 25 cases.

Table 19.30 - continued  
All Lymphoid Neoplasms With Detailed Non-Hodgkin Lymphoma Subtypes<sup>a</sup>

SEER<sup>b</sup> 5-Year Relative Survival (Percent) by Age at Diagnosis

All Races, Males, 2006-2012

Site	All Ages		Ages 0-19		Ages 20-64		Ages 65+	
	Count	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )		
2(b) Non-Hodgkin lymphoma, T-cell	6,288	64.2 ( 62.7 , 65.7 )	86.9 ( 84.3 , 89.1 )	65.7 ( 63.9 , 67.5 )	50.4 ( 47.1 , 53.6 )			
2(b) 1. Precursor Non-Hodgkin lymphoma, T-cell	350	65.6 ( 60.2 , 70.5 )	86.0 ( 79.9 , 90.3 )	47.5 ( 39.0 , 55.5 )	- ( - , - )			
2(b) 2. Mature Non-Hodgkin lymphoma, T-cell	5,914	64.2 ( 62.6 , 65.7 )	87.2 ( 84.2 , 89.7 )	66.7 ( 64.8 , 68.5 )	51.1 ( 47.8 , 54.4 )			
2(b) 2.1. Mycosis fungoides/Sezary syndrome	1,389	88.3 ( 85.0 , 90.9 )	100.0 ( - , - )	90.9 ( 87.7 , 93.3 )	81.8 ( 73.1 , 87.9 )			
2(b) 2.1.1. Mycosis fungoides	1,341	90.3 ( 86.9 , 92.8 )	100.0 ( - , - )	91.9 ( 88.8 , 94.2 )	85.7 ( 76.4 , 91.5 )			
2(b) 2.1.2. Sezary syndrome	48	31.3 ( 13.7 , 50.8 )	- ( - , - )	- ( - , - )	14.3 ( 1.0 , 43.7 )			
2(b) 2.2. Peripheral T-cell lymphoma	3,285	56.3 ( 54.2 , 58.4 )	82.7 ( 75.9 , 87.8 )	62.3 ( 59.6 , 64.8 )	43.2 ( 39.3 , 47.0 )			
2(b) 2.2.1. Peripheral T-cell lymphoma, NOS <sup>c</sup>	1,176	38.6 ( 35.1 , 42.2 )	72.0 ( 49.9 , 85.6 )	44.6 ( 40.0 , 49.1 )	28.5 ( 23.1 , 34.2 )			
2(b) 2.2.2. Angioimmunoblastic T-cell lymphoma	396	40.2 ( 34.1 , 46.1 )	- ( - , - )	49.2 ( 40.5 , 57.3 )	31.6 ( 23.3 , 40.2 )			
2(b) 2.2.3. Subcutaneous panniculitis-like T-cell lymphoma	29	83.2 ( 62.5 , 93.1 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.4. Anaplastic large cell lymphoma, T-cell or null-cell type	701	57.1 ( 52.8 , 61.2 )	85.7 ( 77.0 , 91.3 )	60.7 ( 55.4 , 65.6 )	29.5 ( 20.5 , 39.0 )			
2(b) 2.2.5. Hepatosplenic T-cell lymphoma	36	26.5 ( 12.1 , 43.4 )	- ( - , - )	34.1 ( 16.1 , 53.0 )	- ( - , - )			
2(b) 2.2.6. Enteropathy-type T-cell lymphoma	29	19.3 ( 6.0 , 38.1 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.2.7. Cutaneous T-cell lymphoma, NOS <sup>c</sup>	622	83.7 ( 79.0 , 87.5 )	- ( - , - )	87.2 ( 81.9 , 91.1 )	75.8 ( 67.1 , 82.4 )			
2(b) 2.2.8. Primary cutaneous anaplastic large cell lymphoma	296	88.8 ( 81.5 , 93.3 )	- ( - , - )	95.1 ( 89.5 , 97.8 )	77.1 ( 59.4 , 87.8 )			
2(b) 2.3. Adult T-cell leukemia/lymphoma	836	66.5 ( 62.4 , 70.2 )	88.4 ( 84.6 , 91.3 )	44.1 ( 36.9 , 51.1 )	5.0 ( 0.4 , 19.9 )			
2(b) 2.4. NK <sup>c</sup> /T-cell lymphoma, nasal-type/aggressive NK <sup>c</sup> -cell leukemia	280	42.7 ( 36.0 , 49.3 )	- ( - , - )	41.0 ( 33.5 , 48.4 )	40.4 ( 24.0 , 56.2 )			
2(b) 2.5. T-cell large granular lymphocytic leukemia	39	59.0 ( 39.3 , 74.2 )	- ( - , - )	- ( - , - )	- ( - , - )			
2(b) 2.6. Prolymphocytic leukemia, T-cell	85	17.7 ( 8.3 , 29.9 )	- ( - , - )	21.4 ( 8.8 , 37.5 )	14.2 ( 3.2 , 33.0 )			
2(b) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , T-cell	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(c) Non-Hodgkin lymphoma, unknown lineage	791	58.0 ( 54.0 , 61.7 )	84.4 ( 78.4 , 88.8 )	55.8 ( 49.7 , 61.5 )	39.9 ( 32.7 , 47.1 )			
2(c) 1. Precursor lymphoblastic leukemia/lymphoma, unknown lineage	340	62.9 ( 57.3 , 67.9 )	84.0 ( 78.0 , 88.5 )	38.5 ( 28.0 , 48.9 )	21.3 ( 10.5 , 34.6 )			
2(c) 2. Prolymphocytic leukemia, unknown lineage	-	- ( - , - )	- ( - , - )	- ( - , - )	- ( - , - )			
2(c) 3. Non-Hodgkin lymphoma, NOS <sup>c</sup> , unknown lineage	433	54.3 ( 48.6 , 59.6 )	- ( - , - )	62.9 ( 55.6 , 69.4 )	43.8 ( 35.2 , 52.1 )			
2(*) 1. Total precursor lymphoma/leukemia <sup>d</sup>	4,974	68.1 ( 66.6 , 69.5 )	87.6 ( 86.2 , 88.8 )	39.7 ( 36.9 , 42.6 )	18.9 ( 14.2 , 24.1 )			
3 Composite Hodgkin lymphoma and Non-Hodgkin lymphoma	71	77.1 ( 60.9 , 87.3 )	- ( - , - )	81.1 ( 64.9 , 90.3 )	- ( - , - )			
4 Lymphoid neoplasm, NOS <sup>c</sup>	2,166	49.0 ( 46.3 , 51.6 )	84.6 ( 69.5 , 92.6 )	58.1 ( 54.5 , 61.6 )	39.7 ( 35.7 , 43.7 )			

<sup>a</sup> Morton LM, Turner JJ, Cerhan JR, Linet MS, Treseler PA, Clarke CA, Jack A, Cozen W, Maynadié M, Spinelli JJ, Costantini AS, Rüdiger T, Scarpa A, Zheng T, Weisenburger DD. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood. 2007;110:695-708.

<sup>b</sup> SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

<sup>c</sup> NOS = Not otherwise specified. MALT = Mucosa-associated lymphoid tissue. NK = Natural killer.

<sup>d</sup> Total precursor lymphoma/leukemia is comprised of categories 2(a)1., 2(b)1., and 2(c)1.

- Statistic not displayed due to less than 25 cases.